ANGO Earnings Date: Jan 6, 2027 (Estimated) — AngioDynamics, Inc.
NASDAQ · Healthcare · Medical Instruments & Supplies
Updated
When is ANGO's next earnings date?
AngioDynamics, Inc. (ANGO) is expected to report Q2 2027 earnings on Wednesday, January 6, 2027 at 6:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.08 on revenue of $83.6M.
How did ANGO do in its last earnings report?
In its most recent report on Oct 8, 2026, AngioDynamics, Inc. posted EPS of -$0.04 versus the -$0.11 estimate, a beat of 64.4%. Revenue was $80.9M against a $80.5M estimate. The stock's 1-day post-earnings move was -18.8%.
How much does ANGO stock move after earnings?
ANGO beat EPS estimates in 8 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 14.3% (up or down) in the day after earnings.
About AngioDynamics, Inc.
AngioDynamics, Inc. specializes in the development, manufacturing, and commercialization of a diverse array of medical, surgical, and diagnostic instruments. These products are utilized by healthcare professionals to address conditions such as peripheral vascular disease, facilitate vascular access, and support various oncology and surgical interventions, serving both domestic and international markets. The company's portfolio includes advanced ablation systems like NanoKnife, designed for the precise surgical removal of soft tissues, and Solero microwave and radiofrequency systems, effective in ablating solid cancerous or benign growths. Additionally, they provide BioSentry tract sealant systems, IsoLoc Endorectal Balloons, Alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. Their endovascular therapies segment encompasses solutions for thrombus management, atherectomy procedures, core peripheral products, and the treatment of venous insufficiency. Furthermore, AngioDynamics is a key supplier of vascular access devices, such as peripherally inserted central catheters (PICCs), midline catheters, implantable ports, and dialysis catheters, along with associated accessories. These are primarily employed for short-duration systemic drug delivery, including chemotherapy and antibiotics, marketed under a robust portfolio of brand names such as BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax. The company distributes its offerings directly to a specialized clientele, including interventional radiologists, cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses, while also leveraging established distributor networks. Founded in 1988, AngioDynamics maintains its corporate headquarters in Latham, New York.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-08 | -0.11 | -0.04 | +64.44% | $80.9M | ✅ Beat | -18.82% | -22.13% | — | |
| 2026-07-14 | Q4 2026 | -0.09 | -0.07 | +22.22% | $86.6M | ✅ Beat | +1.76% | +7.32% | +23.29% |
| 2026-04-02 | Q3 2026 | -0.11 | -0.07 | +36.36% | $78.4M | ✅ Beat | -13.65% | -15.49% | -6.53% |
| 2026-01-06 | Q2 2026 | -0.10 | 0.00 | +100.00% | $79.4M | ✅ Beat | -13.53% | -23.05% | -20.71% |
| 2025-10-02 | Q1 2026 | -0.13 | -0.10 | +23.08% | $75.7M | ✅ Beat | +6.05% | +0.45% | +9.67% |
| 2025-07-15 | Q4 2025 | -0.12 | -0.03 | +75.00% | $80.2M | ✅ Beat | -10.18% | -6.65% | -8.20% |
| 2025-04-02 | Q3 2025 | -0.13 | -0.08 | +38.46% | $72.0M | ✅ Beat | +12.42% | -6.83% | -4.87% |
| 2025-01-08 | Q2 2025 | -0.11 | -0.04 | +63.64% | $72.8M | ✅ Beat | +37.66% | +29.47% | +17.45% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q1 FY27 · $80.9M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Med Device | 50.7% | $41.0M | — | $41.6M | $39.5M | $41.3M | $40.7M |
| Med Tech | 49.3% | $39.9M | — | $29.3M | $28.0M | $31.6M | $31.3M |
By region
Q1 FY27 · $80.9M total
| Segment | Share | Revenue | YoY | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q2 FY26 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 87.8% | $71.1M | — | $62.7M | $61.3M | $67.5M | $67.6M |
| Non-US | 12.2% | $9.8M | — | $10.2M | $10.7M | — | $11.8M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.